Recently, Difei Medical Technology (Nanjing) Co., Ltd. (hereinafter referred to as 'Difei Medical') announced the completion of tens of millions of RMB A+ round of financing. This round of financing was invested by Ruiyoukang Fund, a subsidiary of Jiangbei Science and Technology Investment Group. It is used for Difei medical technology research and development, product registration and clinical cooperation promotion, etc.Founded in 2018, Difei Medical was conceived and incubated by Shihe Gene, a leader in the field of tumor precision medicine in China. It is a high-tech enterprise focusing on the development and service of clinical molecular detection technology for pathogenic microorganisms.The company's headquarters is located in Jiangbei New District, a national-level new area. It has a R&D and commercial operation team of more than 100 people from top universities at home and abroad and multidisciplinary.Following prenatal screening and precise diagnosis of tumors, technological advances in high-throughput sequencing and liquid biopsy have promoted the vigorous development of the field of pathogenic microorganisms.The technology has the advantages of not relying on culture, directly acting on clinical samples, unbiased detection, and being able to detect rare and new pathogens.

Recently, the Clinical Laboratory Center of the National Health and Medical Commission announced the results of the external quality evaluation of metagenomic sequencing of lower respiratory tract infections nationwide. A total of 90 enterprises and hospitals across the country participated in the evaluation, with a pass rate of 44.4%. Difei Medical successfully passed the external quality evaluation with high scores .